论文部分内容阅读
目的评估长效胰岛素联合瑞格列奈在2型糖尿病患者中的降糖作用和安全性。方法选择血糖控制欠佳(HbA1c>7.5%,FBG8～13mmol/L)2型糖尿病患者30例,随机分为两组,治疗组(长效胰岛素+瑞格列奈组,15例)和对照组(诺和锐30组,15例),疗程12周,以两组FBG<6.5mmol/L为治疗目标,观察两组血糖控制及低血糖事件发生情况。结果两组患者的FBG、餐后2h血糖较治疗前显著降低(P<0.01),治疗组达标率显著高于对照组,且低血糖发生率低(P<0.01)。结论长效胰岛素联合瑞格列奈能有效控制血糖,不易出现低血糖,有利于全天血糖控制。
Objective To evaluate the hypoglycemic effect and safety of long-acting insulin combined with repaglinide in patients with type 2 diabetes. Methods Thirty patients with type 2 diabetes who had poor control of blood glucose (HbA1c> 7.5%, FBG8 ~ 13mmol / L) were randomly divided into two groups: treatment group (long-acting insulin + repaglinide group, 15 cases) and control group (Novo Rui 30 group, 15 cases), the course of treatment for 12 weeks, with two groups of FBG <6.5mmol / L as the treatment goal, to observe the two groups of glycemic control and hypoglycemic events. Results The FBG and 2h postprandial blood glucose of two groups were significantly lower than those before treatment (P <0.01). The standard rate of treatment group was significantly higher than that of control group, and the incidence of hypoglycemia was low (P <0.01). Conclusion Long-acting insulin combined with repaglinide can effectively control blood glucose, is not prone to hypoglycemia, is conducive to blood glucose control throughout the day.